Cargando…

Effects of Angiotensin Receptor-Neprilysin Inhibitors Versus Enalapril or Valsartan on Patients With Heart Failure: A Systematic Review and Meta-Analysis

Recent studies have focused on treating heart failure, primarily mitigating symptoms and reducing the risk of mortality and other cardiovascular complications. A promising new treatment approach involves using LCZ696, an angiotensin receptor-neprilysin inhibitor (ARNI) comprising sacubitril and vals...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jain, Arpit, Meyur, Shourya, Wadhwa, Lovish, Singh, Kamaldeep, Sharma, Rishi, Panchal, Ishita, Varrassi, Giustino
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cureus 2023
Materias:	Cardiology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10405977/ https://www.ncbi.nlm.nih.gov/pubmed/37554618 http://dx.doi.org/10.7759/cureus.41566

Ejemplares similares

Comparison of Sacubitril/Valsartan Versus Enalapril in the Management of Heart Failure
por: Bano, Shehar, et al.
Publicado: (2021)

Heart Failure Treatments Such As Angiotensin Receptor/Neprilysin Inhibitor Improve Heart Failure Status and Glucose Metabolism
por: Kashiwagi, Yusuke, et al.
Publicado: (2022)

Improvement in quality of life with sacubitril/valsartan in cardiac resynchronization non-responders: The RESINA (RESynchronization plus an Inhibitor of Neprilysin/Angiotensin) registry
por: Campal, José Manuel Rubio, et al.
Publicado: (2021)

Efficacy of Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor-Neprilysin Inhibitors in the Treatment of Chronic Heart Failure: A Review of Landmark Trials
por: Bratsos, Sosipatros
Publicado: (2019)

Sacubitril/valsartan: A novel angiotensin receptor-neprilysin inhibitor
por: Dargad, Ramesh R., et al.
Publicado: (2018)

Comparison of Efficacy and Safety of Angiotensin Receptor-Neprilysin Inhibitors in Patients With Heart Failure With Reduced Ejection Fraction: A Meta-Analysis
por: Haseeb, Muhammad Talha, et al.
Publicado: (2023)

LCZ696 (sacubitril/valsartan), an angiotensin receptor neprilysin inhibitor (ARNI): clinical development in heart failure
por: Lefkowitz, Martin P
Publicado: (2015)

In silico study of inhibitory capacity of sacubitril/valsartan toward neprilysin and angiotensin receptor
por: Jovanović, Jelena Đorović, et al.
Publicado: (2022)

Cost-utility analysis of valsartan, enalapril, and candesartan in patients with heart failure in Iran
por: Ravangard, Ramin, et al.
Publicado: (2023)

Higher persistence with valsartan compared with enalapril in daily practice
por: Siiskonen, Satu J, et al.
Publicado: (2007)

Efficacy of Sacubitril/Valsartan in the Setting of Acute Heart Failure: A Systematic Review
por: Mohyeldin, Moiud, et al.
Publicado: (2021)

Cost-Effectiveness Analysis of Sacubitril/Valsartan Compared to Enalapril for Heart Failure Patients in Indonesia
por: Zakiyah, Neily, et al.
Publicado: (2021)

The neprilysin pathway in heart failure: a review and guide on the use of sacubitril/valsartan
por: Jhund, Pardeep S, et al.
Publicado: (2016)

The Efficacy of Angiotensin Receptor-Neprilysin Inhibitor Versus Angiotensin-Converting Enzyme Inhibitor or Angiotensin Receptor Blocker Post Myocardial Infarction: A Meta-Analysis
por: Kotak, Sohny, et al.
Publicado: (2023)

Angiotensin II Receptor–Neprilysin Inhibitor Sacubitril/Valsartan Improves Endothelial Dysfunction in Spontaneously Hypertensive Rats
por: Seki, Takunori, et al.
Publicado: (2017)

Effect of the angiotensin receptor–neprilysin inhibitor sacubitril/valsartan on the pharmacokinetics and pharmacodynamics of a single dose of furosemide
por: Ayalasomayajula, Surya, et al.
Publicado: (2018)

Sacubitril/Valsartan in Heart Failure Hospitalization: Two Pills a Day to Keep Hospitalizations Away?
por: Sakhamuri, Navya, et al.
Publicado: (2023)

The Effect of Sacubitril-Valsartan on Ventricular Arrhythmia Burden in Patients With Heart Failure With Reduced Ejection Fraction
por: Medeiros, Paulo, et al.
Publicado: (2023)

Angiotensin Receptor-Neprilysin Inhibition (ARNI) in Heart Failure
por: Greenberg, Barry
Publicado: (2020)

Deciphering the Dilemma: Anticoagulation for Heart Failure With Preserved Ejection Fraction (HFpEF)
por: Jyotsna, FNU, et al.
Publicado: (2023)

Dual Angiotensin Receptor-Neprilysin Inhibition With Sacubitril/Valsartan Attenuates Systolic Dysfunction in Experimental Doxorubicin-Induced Cardiotoxicity
por: Boutagy, Nabil E., et al.
Publicado: (2020)

Who ‘nose’, is it the angiotensin receptor neprilysin inhibitor?: a case series of persistent nasal pruritus in heart failure patients receiving sacubitril/valsartan
por: Gan, Jaclyn, et al.
Publicado: (2021)

The comparative effects of sacubitril/valsartan versus enalapril on pulmonary hypertension due to heart failure with a reduced ejection fraction
por: Zhao, Ying, et al.
Publicado: (2022)

Sacubitril–valsartan versus enalapril for the treatment of acute decompensated heart failure in Chinese settings: A cost-effectiveness analysis
por: Hu, Tianyang, et al.
Publicado: (2023)

Effects of neprilysin-renin inhibition in comparison with neprilysin-angiotensin inhibition on the neurohumoral changes in rats with heart failure
por: Dizaye, Kawa, et al.
Publicado: (2019)

The effects of angiotensin receptor neprilysin inhibition by sacubitril/valsartan on adipose tissue transcriptome and protein expression in obese hypertensive patients
por: Stinkens, R., et al.
Publicado: (2018)

Angiotensin II receptor Neprilysin inhibitor (LCZ696) compared to Valsartan attenuates Hepatotoxicity in STZ-induced hyperglycemic rats
por: Alqahtani, Faleh, et al.
Publicado: (2020)

Drug-Induced Liver Injury From Sacubitril-Valsartan Versus a Single Dose of Acarbose
por: Achuthanandan, Supraja, et al.
Publicado: (2022)

Sacubitril-Valsartan Compared With Enalapril for the Treatment of Heart Failure: A Decision-Analytic Markov Model Simulation in China
por: Wu, Yue, et al.
Publicado: (2020)

Cardiovascular biomarkers in patients with acute decompensated heart failure randomized to sacubitril-valsartan or enalapril in the PIONEER-HF trial
por: Morrow, David A, et al.
Publicado: (2019)

Cost-Utility Analysis of Sacubitril-Valsartan Compared with Enalapril Treatment in Patients with Acute Decompensated Heart Failure in Thailand
por: Krittayaphong, Rungroj, et al.
Publicado: (2021)

Effect of sacubitril/valsartan vs. enalapril on changes in heart failure therapies over time: the PARADIGM‐HF trial
por: Bhatt, Ankeet S., et al.
Publicado: (2021)

Real-world use patterns of angiotensin receptor-neprilysin inhibitor (sacubitril/valsartan) among patients with heart failure within a large integrated health system
por: Kim, Brendan J, et al.
Publicado: (2022)

Cocaethylene: When Cocaine and Alcohol Are Taken Together
por: Pergolizzi, Joseph, et al.
Publicado: (2022)

Effect of Valsartan on N-Terminal Pro-Brain Natriuretic Peptide in Patient With Stable Chronic Heart Failure: Comparison With Enalapril
por: Lee, Young Soo, et al.
Publicado: (2011)

Safety and efficacy of ARNI (valsartan/sacubitril) vs ACEI (enalapril) in acute heart failure – A prospective observational study
por: Bhat, Tahir Saleem, et al.
Publicado: (2022)

Cost-Effectiveness of Sacubitril/Valsartan Compared with Enalapril in Patients with Heart Failure with Reduced Ejection Fraction: A Systematic Review
por: Rezapour, Aziz, et al.
Publicado: (2022)

Angiotensin receptor-neprilysin inhibitors: clinical potential in heart failure and beyond
por: Singh, Jagdeep SS, et al.
Publicado: (2015)

Getting the “Right” Perspective on Angiotensin Receptor–Neprilysin Inhibition in Heart Failure
por: Verbrugge, Frederik H., et al.
Publicado: (2020)

Angiotensin receptor blocker neprilysin inhibitors
por: Usuda, Daisuke, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_0ag6n4it2p7in5go69n9i7iv7l